艰难梭菌疫苗研究的现状与展望  

Current Situation and Future Development of the Vaccine against Clostridium Difficile

作　　者：杨晓强[1] 陈学清[2] 

机构地区：[1]广州军区广州总医院消化内科,广东广州510010 [2]广州医学院第一附属医院消化内科,广东广州510120

出　　处：《医学与哲学（B）》2011年第8期38-40,共3页Medicine & Philosophy(B)

基　　金：国家自然科学基金自由申请面上项目;项目编号:30570839;广东省自然科学基金;项目编号:05004735;广东省教育部产学研结合项目;项目编号:2009B090300354

摘　　要：艰难梭菌是引起伪膜性肠炎的致病菌。目前国内外均出现了同时耐两种主要治疗药物——甲硝唑、万古霉素的菌株,疫苗研究是防治艰难梭菌的重要手段。国外研制艰难梭菌疫苗近20年,取得了一定进展,本文将对现有的艰难梭菌疫苗的研究现状进行总结,并对疫苗的发展进行展望。Clostridium difficile（CD） is the pathogen of pseudomembranous colitis （PMC）. Metronidazole and Vancomycin are the major treatment drugs for PMC. However, clostridium difficile has been found to possess multiple-antibiotic resistant genes and clostridium difficile clinical isolates resistant to both Vancomycin and Metronidazole have been reported, which increase the difficulty for treatment of clostridium difficile in the future. For all these reasons, the study of vaccine against CD is very important. The vaccines against clostridium difficile have been studied in abroad for almost 20 years and great progress has been achieved in the study of clostridium difficile vaccine. In this article we will have a review of the clostridium difficile vaccine.

关 键 词：艰难梭菌 伪膜性肠炎 疫苗 

分 类 号：R378.8[医药卫生—病原生物学]